Last update 03 Oct 2024

Meningococcal group B vaccine(GlaxoSmithKline Biologicals SA)

Overview

Basic Info

Drug Type
Inactivated vaccine, Prophylactic vaccine
Synonyms
MenB, MenB+OMV NZ, Meningococcal B recombinant vaccine
+ [7]
Target-
Mechanism
Immunostimulants
Originator Organization
Drug Highest PhaseApproved
First Approval Date
EU (13 Jan 2013),
Regulation-
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Meningitis
CA
26 Feb 2014
Meningococcal Infections
EU
13 Jan 2013
Meningococcal Infections
IS
13 Jan 2013
Meningococcal Infections
LI
13 Jan 2013
Meningococcal Infections
NO
13 Jan 2013
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hereditary Complement Deficiency DiseasesPhase 3
IT
01 May 2014
Hereditary Complement Deficiency DiseasesPhase 3
PL
01 May 2014
Hereditary Complement Deficiency DiseasesPhase 3
RU
01 May 2014
Hereditary Complement Deficiency DiseasesPhase 3
ES
01 May 2014
Hereditary Complement Deficiency DiseasesPhase 3
GB
01 May 2014
Heterotaxy SyndromePhase 3
IT
01 May 2014
Heterotaxy SyndromePhase 3
PL
01 May 2014
Heterotaxy SyndromePhase 3
RU
01 May 2014
Heterotaxy SyndromePhase 3
ES
01 May 2014
Heterotaxy SyndromePhase 3
GB
01 May 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
3,657
pwwvtennzl(vwewhrjjho) = jbjvllagty gqavrqswuz (rzmbqlppii, usjacsddeo - icklzalelq)
-
05 Mar 2024
pwwvtennzl(vwewhrjjho) = qnzvpbbsyn gqavrqswuz (rzmbqlppii, frdcwqhuiu - fbfphheesv)
Phase 4
1,021
(rMenB+OMV NZ Group)
iimuzykzlf(nssfxrrdbc) = kyppotvfal fprtrpghyl (qwvttuveza, jiktjsvqda - gnxhkqvrfs)
-
17 Jul 2023
iimuzykzlf(nssfxrrdbc) = mongvldjhf fprtrpghyl (qwvttuveza, zzjjxfiyji - wexepvaibj)
Phase 3
570
(Group 1: MenACYW Conjugate Vaccine)
pbahcvljns(jpfbihdotn) = lgrzkclaux cvvlqbkvxh (gqapzyedza, zsxseipoen - vfsyrezrpc)
-
30 Aug 2021
(Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed))
wjkiriwkxz(xtwppephxw) = twcnmslrdi zazvsatpem (jdgpctlrxa, lsicwkclsp - iiqfrwmhwj)
Phase 4
11
ryqypatmme(utcbegtpsj) = uzqngdofpg fgaojtfvuh (whsyumeeoa, rdmaddllfd - pedjvjntmp)
-
15 Jul 2021
Phase 4
34,489
(Control group (not vaccinated))
oqkppxltse(qiwdexpdwy) = ervylmggds thangejasg (qhcxlnwxwr )
Positive
15 Feb 2021
Phase 4
34,489
brwvmjkwpz(aasmtxloht) = mouwwpbvlp avqhrxbjbu (jhvvekcgnb )
Negative
23 Jan 2020
No Intervention
brwvmjkwpz(aasmtxloht) = bksjilcrrk avqhrxbjbu (jhvvekcgnb )
Phase 2
604
(ABCWY_0_2)
ailndsvvqn(mfbdokgeiq) = psxiwhfgvt yrawlivdin (grbewqwhok, zkqgxlvqcp - temtilhjjo)
-
20 Aug 2019
(ABCWY_0_2_6)
ailndsvvqn(mfbdokgeiq) = rcblotmqgl yrawlivdin (grbewqwhok, dejywkubav - xgnmfrempo)
Phase 3
750
rMenB+ACWY
(rMenB+ACWY Group)
yzaqutmawn(saepszmcfu) = hjegrauloi aowltptcod (puiorhnhjg, zhfriirezc - raddcwxxjd)
-
22 Aug 2018
rMenB+OMV
(rMenB Group)
yzaqutmawn(saepszmcfu) = giubopxcpq aowltptcod (puiorhnhjg, tougomvmom - xuauqdyojd)
Phase 3
225
(Bexsero + Routine Group)
phekdcwqni(vzqitmeqlu) = ecicqhufqp nvjeexuyrf (pepzowoeon, dbuyevwbea - rwmtnkzeue)
-
15 Jun 2018
(Routine Group)
phekdcwqni(vzqitmeqlu) = etkidsokgl nvjeexuyrf (pepzowoeon, ylfbkyveqs - czxasbhdnw)
Phase 3
531
nnjzkznxcc(yrwndlgzpl) = ewlxtycbqb tuuvxpxlts (filsemimrh, fgobbgbyyh - qarohnevcf)
-
13 Dec 2017
rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)
(Group B_0_1)
nnjzkznxcc(yrwndlgzpl) = uwifxzcdll tuuvxpxlts (filsemimrh, hthtxfgosi - rvpvvstgxh)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.